HOME >> MEDICINE >> NEWS
Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome

Scientists at Johns Hopkins have used a commonly prescribed blood pressure medicine, losartan (Cozaar), to prevent a potentially fatal weakening of arteries in mice with Marfan syndrome.

As a result, efforts are already under way with the National Heart, Lung and Blood Institute and its affiliated network of hospitals in the Pediatric Heart Health Network and The Johns Hopkins Hospital to begin a clinical trial for people with Marfan syndrome, which is expected to start in the fall.

"The results of our study in mice greatly increase the likelihood that losartan will also serve as an effective treatment in humans and quickly, because it is already approved for use in the United States as a safe and effective treatment for hypertension," says study senior author, Harry (Hal) Dietz, M.D., a professor at the McKusick-Nathans Institute of Genetic Medicine at The Johns Hopkins University School of Medicine.

The Hopkins findings, to be published in the journal Science online April 6, are considered a breakthrough discovery, researchers say, because they are the first to identify a drug that can prevent Marfan syndrome's most life-threatening complications from developing and potentially reverse the damage already done. Marfan syndrome can lead to a fatal tear or rupture in the aorta, the body's main blood vessel that carries blood away from the heart. The disease is often diagnosed in childhood or early adulthood, when people are still young enough to consider long-term therapies.

"It is very exciting that an existing medication has proven capable of not only treating the problems of Marfan syndrome, but also disrupting the biological pathway that precipitated them," says cardiac geneticist Daniel P. Judge, M.D., an assistant professor at Hopkins and its Heart Institute and co-lead author of the study.

"Until now, surgery has been our main option for repairing an aorta at risk of rupturing," says cardiac surgeon Vincent Gott,
'"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
6-Apr-2006


Page: 1 2 3 4 5

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Commonly recommended sedative does not improve infant sleep
4. Commonly used drug may prevent fetal alcohol syndrome
5. Commonly used antidepressants may also affect human immune system
6. Even low levels of weekly exercise drive down blood pressure
7. Chemotherapy with bevacizumab increases risk of blood clots in arteries
8. High blood pressure problems largely misunderstood by sufferers
9. Trial stops after stroke and mortality significantly reduced by blood
10. Program announced to improve care in developing areas for patients with blood disorders
11. New nutritional research: College students face obesity, high blood pressure, metabolic syndrome

Post Your Comments:
(Date:5/18/2013)... who swallow high-powered magnets often need surgery and other ... new study. The researchers, from the Louisiana State ... than 79 percent of children who swallowed very strong ... in which a tube containing a camera is inserted ... cases can be treated through observation or by pumping ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... Inc.’s Gynecare pelvic mesh products continue to move forward ... County Superior Court, Bernstein Liebhard LLP reports. According to ... Management Conference in the Ethicon pelvic mesh litigation will ... indicate that 2,755 complaints have been filed in the ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 TheBeautyPlace.com answers ... Pattern hair loss is not a result of stress, ... to Men’s Fitness Magazine, 70% of men suffer from ... Strength is renowned for hair transplant surgery, but ... male pattern baldness known as Bosley Professional Strength. Their ...
(Date:5/18/2013)... Philadelphia, PA (PRWEB) May 18, 2013 ... as indulging in healthy snacks and drinking more water ... weight loss and, ultimately, a healthier lifestyle overall. ... to achieve the best weight loss can be difficult ... treatments into their diet plans to help patients get ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 3
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation (NYSE: ... the annual EuroPCR Scientific Program May 21-24 in ... to present a particularly rich and diversified set of ... Dawkins , M.D., global chief medical officer, Boston ... be presented, including the NG PROMUS trial, which evaluated ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies that ... that CEO Doug Godshall is scheduled ... 11:00 a.m. EDT on Monday, May 20, 2013.  The conference ... York Hotel. A live webcast of the Company,s ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
Cached News: